Rennova Health, Inc.
RNVA · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | 0.00 | -0.01 |
| FCF Yield | 7.86% | -9.27% | 7,179.50% | 30.95% |
| EV / EBITDA | -7.24 | -58.17 | 5.04 | 11.40 |
| Quality | ||||
| ROIC | 4.48% | 2.94% | -10.27% | -5.20% |
| Gross Margin | 48.30% | 48.94% | 71.29% | 60.39% |
| Cash Conversion Ratio | -0.14 | 0.44 | 1.72 | 1.42 |
| Growth | ||||
| Revenue 3-Year CAGR | 79.63% | 97.69% | 76.41% | 52.83% |
| Free Cash Flow Growth | 188.67% | -113.54% | 133.40% | -2.85% |
| Safety | ||||
| Net Debt / EBITDA | -5.66 | -46.19 | 5.03 | 9.35 |
| Interest Coverage | -18.18 | -1.43 | 4.86 | 1.36 |
| Efficiency | ||||
| Inventory Turnover | 10.03 | 6.79 | 7.79 | 7.03 |
| Cash Conversion Cycle | -395.63 | -460.16 | -541.54 | -430.64 |